Home page > Health, wealth and equity | Good governance for health

Transparency


Please find all related articles below.



[Joint open letter] EPHA co-signs letter from group of civil society and farming organisations on ongoing reform of DG Agri advisory groups


Welcoming the decision by the European Commission on the reform of the functioning and composition of advisory groups - and to stress the importance of having a balance between the different civil society groups focused on economic, social and environmental issues - EPHA joins efforts with other non-governmental organisations and co-signs an open letter to EU Commissioner for Agriculture, Dacian Ciolos. The letter, entiled ’Reform of DG Agriculture advisory group system’ is (...)
27/01/2014

[Joint Open Letter] Litigation from multinationals could block progressive EU environmental and social policies


Brussels, 9 January 2014 - Ten leading European Public Health, Transparency and Environment NGOs, including EPHA, signed an open letter which highlights serious concerns with the mechanism called the Investor State Dispute Settlement (ISDS) that risks becoming part of the Transatlantic Trade and Investment Partnership (TTIP). This letter has been published on[Euractive’s website. The European Commission has repeatedly promised civil society that the ongoing Transatlantic Trade and (...)
14/01/2014

[Corporate sovereignty] How trade policy gives companies tools to delay measures to protect public health


On 3 December 2013, Members of the European Parliament (MEP) Linda McAvan (S&D) and Carl Schlyter (Greens) hosted a debate in the European Parliament on the 514 cases that corporations have brought against governments. Some of the examples presented included the international tobacco giant Philip Morris suing the governments of Uruguay and Australia for introducing plain cigarette packaging. This debate is particularly relevant in light of current negotiations between the EU and the (...)
13/12/2013

[Joint press release] Leaked Commission research documents raise questions about whose interests are being prioritised


1 October, Brussels -Scientists, public health researchers and NGOs have reacted with grave concern in light of leaked copies of the European Commission’s proposed Health Research Programme 2014-2015 (part of Horizon2020) circulating in Brussels. They have raised questions regarding the preparation of this draft, given its failure to address the major personal, social, environmental and occupational risk factors of disease in favour of narrow research parameters focusing on (...)
07/10/2013

Health priorities of the Lithuanian Presidency of the EU Council


The Lithuanian Presidency, which will be the last full EU Council presidency before the European elections of 2014, will focus its efforts in attaining a credible, growing and open Europe, building on the cooperation with its Trio partners. Lithuania will focus its efforts in the following health issues. The Lithuanian Priorities for health Advancing legislative initiatives Revision of the Tobacco Products Directive (high priority) Lithuania has confirmed its commitment to continue (...)
08/07/2013

[Joint Press Statement] Access to medicines in Europe: The EU cannot save banks while sacrificing people’s health


Brussels, 17 May – In a seminar hosted yesterday by the Group of the Progressive Alliance of Socialists & Democrats (S&D) in the European Parliament and the Member of the European Parliament (MEP) Alejandro Cercas (S&D, Spain), six MEPs from various political groups (1) along with representatives of governments, leading academics, researches and public health organisations (2) met to raise awareness about one of the most alarming issues that European healthcare systems (...)
17/05/2013

[Seminar report] Can EU Citizens Afford Their Medicines?


This high level meeting revolved around various political processes linked to the economic crisis. Some of the topics discussed include implementation of the Europe 2020 strategy, as well as pharmaceutical legislation for ensuring that people living in Europe have access to a wide range of quality and affordable medicines. The meeting hosted by Mr Alejandro Cercas, MEP (Spain,S&D) and by the Socialists and Democrats in the European Parliament (S&D Group) served to assess the impact (...)
29/04/2013

Clinical trials: Exploring the limits of transparency


Glenis Willmott MEP (S&D, UK) took the initiative to bring together experts to discuss the extent to which more transparency could be workable in non-commercial clinical trials. The debate, which took place in the European Parliament on 10 April, served to present the key arguments for and against increased transparency in the context of administrative and data reporting requirements for academic researchers and patient safety. EPHA’s Position on Clinical Trials urges political (...)
25/04/2013

EP resolution underlines the need for action on medicines access problem


On 18 April, the European Parliament (EP) voted on a Resolution on the impact of the financial and economic crisis on human rights. The resolution highlighted some of the global impacts of the crisis on the right to health. EPHA applauds the EP’s recognition of the multiple impacts of the crisis on ordinary people and the need to further champion public health across Europe. The Resolution states that "the rising price of medicines (by up to 30%) is having a negative impact on the (...)
18/04/2013

Can Health Impact Assessment methods be used to tackle global health equity?


A recent survey has examined if current health impact assessment (HIA) methods could be used to tackle global health equity. The poll shows that HIA do not address the issue of equity adequately. Existing HIAs will therefore require new, more sensitive tools measurements. The study looks at whether health equity impact assessments can be used to measure economic agreements, market regulation, and public policies. The results has proven that in current HIAs, equity is not addressed (...)
18/03/2013